179 results on '"Simpson, Eric"'
Search Results
2. Topical Steroid Withdrawal Treated with Ruxolitinib Cream
3. Dupilumab treatment improves signs, symptoms, quality of life and work productivity in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial
4. The Social and Home Environment: Impacts of Determinants of Health on Atopic Dermatitis, Pathways Toward Solutions, and Unique Considerations for Rural and Remote North American Indigenous Populations
5. Cutaneous Ceramide Synthase 1 (CERS1) Gene Expression is a Biomarker of Staphylococcus aureus Abundance and Severity of Atopic Dermatitis
6. Dupilumab Reduction of IgE Levels and Probability of Atopic Dermatitis Flares – Analysis of A Randomized Placebo-Controlled 52-Week Study
7. Efficacy and Safety of Ruxolitinib Cream Among Children With Atopic Dermatitis Aged 2 to 6 Years and 7 to <12 Years: Results from a Phase 3 Double-Blind Vehicle-Controlled Study
8. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment
9. Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis – Authors' reply
10. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
11. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
12. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
13. Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial
14. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies
15. Practical management of ocular surface disease in patients with atopic dermatitis, with a focus on conjunctivitis: A review
16. Dupilumab Treatment Reduces Total IgE Levels in Patients 6 Months and Older with Moderate-to-Severe Atopic Dermatitis
17. Demographic differences in self-reported barriers and facilitators to eczema clinical trial participation among adult patients and caregivers of pediatric patients.
18. The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice
19. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
20. Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)
21. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials
22. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
23. Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies
24. 34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies
25. 33233 Long-term efficacy (to 68 weeks) of baricitinib in adult patients with moderate to severe atopic dermatitis (AD) who were treatment responders or partial responders and originally included in the combination topical corticosteroids study BREEZE-AD7
26. 33968 Time to improvement in daily signs and symptoms associated with atopic dermatitis (AD) in patients with moderate-to-severe AD in pooled monotherapy studies of abrocitinib
27. 32097 Factors associated with eczema clinical trial participation in adults
28. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial
29. 33748 Real-world insights into quality improvement in atopic dermatitis care
30. 33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study
31. 35163 Ruxolitinib cream provided progressive improvement in patients with atopic dermatitis who did not achieve Investigator’s Global Assessment treatment success at week 8: Pooled results from 2 phase 3 studies
32. 32824 Factors associated with treatment satisfaction in atopic dermatitis: A cross-sectional, population-based study examining patient and physician perspectives
33. 33298 Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
34. The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study
35. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
36. The HOME Core outcome set for clinical trials of atopic dermatitis
37. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis
38. Are skin microbes with lantibiotic biosynthesis genes reduced in atopic dermatitis subjects who are culture positive for Staphylococcus aureus?
39. Effect of Dupilumab on the Host-Microbe Interface in Atopic Dermatitis
40. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
41. Efficacité de l’abrocitinib chez les patients sévères difficiles à traiter présentant une dermatite atopique modérée à sévère dans l’étude de phase III JADE COMPARE
42. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies
43. 27375 Dupilumab provides early and sustained improvement of sleep disturbance in children ≥ 6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
44. 26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies
45. 27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE
46. 26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5
47. 27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: Pooled Results from two phase 3 studies
48. 28171 Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: Combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2)
49. 27915 Rapid skin improvement with upadacitinib with or without topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)
50. 26839 Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.